| human | Q5 |
| P496 | ORCID iD | 0000-0002-1875-202X |
| P734 | family name | Musoke | Q37541078 |
| Musoke | Q37541078 | ||
| Musoke | Q37541078 | ||
| P106 | occupation | researcher | Q1650915 |
| Q35792581 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". |
| Q90879751 | A hospital-based birth defects surveillance system in Kampala, Uganda |
| Q38877926 | Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala |
| Q36486323 | An Early Morning Sputum Sample Is Necessary for the Diagnosis of Pulmonary Tuberculosis, Even with More Sensitive Techniques: A Prospective Cohort Study among Adolescent TB-Suspects in Uganda |
| Q34059986 | Analysis of HIV diversity using a high-resolution melting assay |
| Q34786687 | Analysis of HIV tropism in Ugandan infants |
| Q33874942 | Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda |
| Q36983684 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. |
| Q34494986 | Antiretroviral treatment for children with peripartum nevirapine exposure |
| Q33886570 | Association of HIV diversity and survival in HIV-infected Ugandan infants. |
| Q46971460 | Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission |
| Q37357700 | Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals |
| Q38878833 | Bacteraemia in severely malnourished children in an HIV-endemic setting |
| Q38866001 | Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe |
| Q99201274 | Barriers and facilitators for transitioning of young people from adolescent clinics to adult ART clinics in Uganda: unintended consequences of successful adolescent ART clinics |
| Q37033083 | Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy |
| Q34869423 | Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda |
| Q91952341 | Caregiver socioemotional health as a determinant of child well-being in school-aged and adolescent Ugandan children with and without perinatal HIV exposure |
| Q38882434 | Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). |
| Q56911275 | Comparative effects of three methods of promoting breastfeeding among human immunodeficiency virus-infected women in Uganda: a parallel randomized clinical trial |
| Q46937504 | Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. |
| Q33561750 | Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants |
| Q38880681 | Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. |
| Q35947561 | Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. |
| Q57822546 | Courage and confidence to stop lying: caregiver perspectives on a video to support paediatric HIV disclosure in Kampala, Uganda |
| Q38877473 | Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. |
| Q38875455 | Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland |
| Q38880584 | Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. |
| Q33926411 | Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda |
| Q104610402 | Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration |
| Q37103307 | Effect of subsequent pregnancies on HIV disease progression among women in the Mulago Hospital MTCT-Plus program in Uganda |
| Q34634644 | Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial |
| Q34657178 | Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial |
| Q35788891 | Epidemiology of tuberculosis in children in Kampala district, Uganda, 2009-2010; a retrospective cross-sectional study |
| Q91497550 | Erratum to: Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012 |
| Q36167273 | Estimating Regression Parameters in an Extended Proportional Odds Model |
| Q36699672 | Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study |
| Q27690864 | Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. |
| Q38875948 | Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials |
| Q58591707 | Factors Influencing the Risk of Becoming Sexually Active Among HIV Infected Adolescents in Kampala and Kisumu, East Africa |
| Q36763303 | Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. |
| Q35078481 | Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda |
| Q38880822 | Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine. |
| Q38876345 | HIV-1 tropism and survival in vertically infected Ugandan infants. |
| Q33793608 | Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study |
| Q34229329 | Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa |
| Q37364479 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. |
| Q38882753 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. |
| Q38866322 | Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine. |
| Q34231039 | Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival |
| Q38874717 | Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time |
| Q36218701 | Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. |
| Q113265259 | Mobile tablets for real-time data collection for hospital-based birth defects surveillance in Kampala, Uganda: Lessons learned |
| Q93212232 | Mortality among children under five years admitted for routine care of severe acute malnutrition: a prospective cohort study from Kampala, Uganda |
| Q38880827 | Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. |
| Q98383901 | PMTCT Option B+ 2012 to 2018 - Taking stock: barriers and strategies to improve adherence to Option B+ in urban and rural Uganda |
| Q46328871 | Partnerships for Global Child Health |
| Q38878562 | Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission |
| Q45285923 | Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. |
| Q38871183 | Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial |
| Q37708677 | Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children |
| Q38884220 | Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda |
| Q38881616 | Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda |
| Q30569674 | Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission |
| Q33719217 | Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay |
| Q38879379 | Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. |
| Q38880191 | Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns |
| Q30539434 | Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial |
| Q35475930 | Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). |
| Q46534172 | Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. |
| Q104143688 | Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS |
| Q92128503 | Serum Vitamin D is Differentially Associated with Socioemotional Adjustment in Early School-Aged Ugandan Children According to Perinatal HIV Status and In Utero/Peripartum Antiretroviral Exposure History |
| Q92543920 | Serum n-6 Fatty Acids are Positively Associated with Growth in 6-to-10-Year Old Ugandan Children Regardless of HIV Status-A Cross-Sectional Study |
| Q57207542 | Short Communication: HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D |
| Q53691502 | Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. |
| Q36802222 | Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years |
| Q38857294 | Successful Global Health Research Partnerships: What Makes Them Work? |
| Q38883658 | Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). |
| Q34498482 | The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women |
| Q38877518 | The costs associated with adverse event procedures for an international HIV clinical trial determined by activity-based costing |
| Q36987446 | The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease |
| Q38871341 | The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, Janu |
| Q92848407 | Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network |
| Q26864053 | Treatment of young children with HIV infection: using evidence to inform policymakers |
| Q28602123 | Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy |
| Q34524522 | Two year mortality and associated factors in a cohort of children from rural Uganda |
| Q38660444 | Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation |
| Q36322938 | Use of a high resolution melting assay to analyze HIV diversity in HIV-infected Ugandan children |
| Q93147502 | Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda |
| Q37393551 | Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. |
| Q34640041 | Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda |
| Q47133943 | Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial |
| Q30607444 | When enough is enough: how the decision was made to stop the FEAST trial: data and safety monitoring in an African trial of Fluid Expansion As Supportive Therapy (FEAST) for critically ill children |
Search more.